NeoGenomics (NEO) Tops Q2 EPS by 3c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
Needham Reiterates Buy Rating on Neogenomics (NEO)
July 30, 2024 6:04 AM EDTNeedham analyst Mike Matson reiterated a Buy rating and $19.00 price target on Neogenomics (NASDAQ: NEO).
The analyst comments "NEO's 2Q24 revenue and EBITDA beat consensus and management raised 2024 revenue and EBITDA guidance. Revenue growth slowed to 12% Y/Y in 2Q24 from 14% in 1Q24,... More
